An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples